Post-earnings recap
Reported
Thu, Jul 23, 2026
EPS actual
$3.12
EPS est.
$2.81
EPS surprise
+10.87%
1-day move
+8.61%
Quest Diagnostics reported better-than-expected earnings per share, which led to a significant stock increase of 8.61%. The positive EPS surprise indicates stronger profitability than anticipated, although no revenue figures or management commentary were provided. Investors may view this as a sign of operational strength despite the lack of detailed guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.12 | N/A | +10.87% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing services in the health care sector. The company plays a crucial role in patient care by offering a wide range of laboratory tests that help diagnose diseases and monitor health conditions. As the health care industry increasingly focuses on personalized medicine and preventive care, Quest's services are more important than ever.
Last quarter
In Q1-2026, Quest Diagnostics reported an EPS of $2.50, exceeding expectations by 5.44%. The stock reacted positively, gaining 4.45% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+3.96%
Avg 1-day reaction
+5.47%
Overall, expectations are mixed as analysts await clarity on revenue growth and test volumes in the upcoming earnings report.
Bull case
If Quest Diagnostics continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its services, leading to a positive stock reaction.
Bear case
Conversely, if the company fails to meet expectations for test volumes or revenue growth, it may raise concerns about its market position and impact the stock negatively.
The print will turn on these.
Q1
What will the test volume growth be compared to last quarter?
Test volume is a critical driver of revenue, and any significant changes could impact future earnings.
Q2
How is management addressing competitive pressures in the diagnostics market?
Understanding management's strategy in a competitive landscape will help gauge the company's ability to maintain its market position.
—
Est. EPS
$0.34
Est. Rev
$86M
Impl. Move
±11.2%
Why consensus could be wrong
The Street may underestimate Quest's ability to leverage its existing infrastructure to drive test volume growth despite competitive pressures.
Supporting evidence
Historical performance shows consistent EPS beats, indicating strong operational execution.
The options market is pricing a smaller move than historical averages, suggesting potential undervaluation of upcoming volatility.
Management's previous commitments to enhance testing capabilities could lead to unexpected revenue growth.
Key risk
If test volumes exceed expectations, it could significantly alter the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter, the focus is on how well Quest Diagnostics can maintain its growth trajectory amid competitive pressures and market changes.
Bull confirmed if
Test volume growth of +5% YoY or better would confirm strong demand and support the bull case.
Bear confirmed if
A decline in test volumes or revenue growth below 2% would confirm the bear case.
What the market is pricing for the move.
Implied Move
±2.31%
Historical Avg
±6.2%
The options market is pricing a modest move in either direction, indicating uncertainty about the upcoming earnings report.
Options are pricing ±2.3% while DGX has averaged ±6.2% over the last 8 prints — setup is pricing cheap.
ATM IV
0.3%
30d HV
24.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
98.87%
of float
Insider
0.43%
of float
Holders
1,522
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
9,275,411 sh · $2.1B
8.40%
1.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Quest beats expectations, history suggests a potential stock increase of around +3.85%, confirming strong demand.
In line / cautious
If results are in line but management provides cautious commentary, the stock may react moderately, reflecting uncertainty.
Miss
Should the company miss expectations, history suggests a potential decline of around -3.03%, raising concerns about future performance.
The lines on the call that would change the story.
Vanguard Capital Management LLC
7,233,394 sh · $1.6B
6.55%
1.2%
Vanguard Portfolio Management LLC
6,131,045 sh · $1.4B
5.55%
0.8%
State Street Corporation
5,516,643 sh · $1.3B
5.00%
2.5%
Price (T.Rowe) Associates Inc
5,444,986 sh · $1.2B
4.93%
-13.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.